FDA added bemotrizinol to the list of permitted sunscreen active ingredients, marking the first new active ingredient added to the over-the-counter sunscreen monograph since the late 1990s.
FDA approved Decnupaz (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval is supported by data from the phase I/II CADENZA trial, a global study evaluating the safety and efficacy of Decnupaz for BPDCN.
